For GSK's Advair inhaler, what's the optimal trade-off between extending patent protection and improving accessibility?

Introduction

The optimal trade-off between extending patent protection and improving accessibility for GSK's Advair inhaler presents a complex challenge. This scenario involves balancing the company's financial interests with broader public health considerations. I'll analyze this trade-off by examining the product's context, stakeholder impacts, and potential strategies to navigate this dilemma.

Step 1

Clarifying Questions (3 minutes)

• Based on the current market landscape, I'm thinking Advair might be facing increased competition from generics. Could you provide more context on the current patent status and market position of Advair?

Why it matters: Helps understand the urgency of the trade-off decision Expected answer: Patent nearing expiration, facing generic competition Impact on approach: Would influence the balance between protection and accessibility strategies

• Considering GSK's overall portfolio, I'm curious about Advair's strategic importance. How does Advair contribute to GSK's revenue and align with its long-term respiratory disease strategy?

Why it matters: Determines the resources and priority for this decision Expected answer: Significant revenue contributor, key to respiratory portfolio Impact on approach: Would justify more aggressive patent protection efforts

• Looking at patient demographics, I'm wondering about the current accessibility of Advair. Can you share insights on patient affordability and access challenges?

Why it matters: Helps quantify the potential impact of improving accessibility Expected answer: Significant portion of patients struggle with affordability Impact on approach: Would emphasize the need for accessibility improvements

• Considering potential technical innovations, are there any upcoming formulation improvements or delivery mechanism enhancements for Advair?

Why it matters: Could influence patent extension strategies Expected answer: Some incremental improvements in pipeline Impact on approach: Would explore patent extension through product enhancements

• Given the global nature of the pharmaceutical market, I'm curious about regional variations in Advair's patent status and accessibility. How does this vary across key markets?

Why it matters: Informs a potentially segmented approach to the trade-off Expected answer: Varying patent expiration dates and accessibility challenges by region Impact on approach: Would consider region-specific strategies for patent protection and accessibility